ANDA 90854, held by Teva Pharms USA. Eptifibatide.
As of Nov 14, 2026, ANDA 90854 (Eptifibatide), held by Teva Pharms USA, was first approved by FDA on Jun 12, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 12, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Eptifibatide2MG/ML ยท injectable;injection | Eptifibatide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
